Intrastriatal DNQX induces rotation and pallidal Fos in the 6-OHDA model of Parkinson's disease.
The 6-hydroxydopamine rat model of Parkinson's disease was combined with intracerebral drug infusions to examine the influence of glutamate receptors on striatal output activity. When infused into the dopamine-denervated striatum, the AMPA-kainate receptor antagonist DNQX dose-dependently elicited contralateral rotation and ipsilateral Fos immunoreactivity (Fos-IR) in the globus pallidus, a target nucleus of striatal output. DNQX did not elicit rotation or Fos-IR in unlesioned or partially lesioned rats. In addition, the NMDA receptor antagonist AP-5 failed to induce rotation and had minimal effects on pallidal Fos-IR in lesioned rats. These results suggest a role for striatal AMPA-kainate receptors in the pathology and treatment of Parkinson's disease.
Schuller
J J
JJ
Department of Psychobiology, University of California, Irvine, 92717-4550, USA.
Marshall
J F
JF
D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D008297:Male; D016627:Oxidopamine / Q000494:pharmacology*; D010300:Parkinson Disease / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000187:drug effects*; D011810:Quinoxalines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012399:Rotation
D016760:Proto-Oncogene Proteins c-fos; D011810:Quinoxalines; C056723:FG 9041; D016627:Oxidopamine